Ubs Group Ag Ascendis Pharma A/S Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ubs Group Ag holds 12,425 shares of ASND stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,425
Previous 15,921
21.96%
Holding current value
$1.69 Million
Previous $2.17 Million
14.56%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.32 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$700 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$680 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$602 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$571 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.61B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...